<DOC>
	<DOCNO>NCT00065260</DOCNO>
	<brief_summary>Severe aplastic anemia , characterize pancytopenia hypocellular bone marrow , effectively treat immunosuppressive therapy , usually combination antithymocyte globulin ( ATG ) cyclosporine ( CsA ) . Survival rate follow regimen equivalent achieve allogeneic stem cell transplantation . However , approximately 1/3 patient show blood count improvement ATG/CsA . General experience small pilot study suggest patient may benefit immunosuppression . Furthermore , analysis clinical data suggest patient poor blood count response single course ATG , even transfusion-independence achieve , markedly bad prognosis patient robust hematologic improvement . The management case uncertain . This study enroll patient either refractory h-ATG ( continue severe pancytopenia ) modest improvement blood count ( weak hematologic responder ) receive immunosuppressive therapy , deliver either rabbit ATG ( Thymoglobulin , r-ATG ) humanize monoclonal antibody T-cells , alemtuzumab ( Campath-1H ) . Primary endpoint response rate 3 month define longer meet criterion severe aplastic anemia . Relapse , robustness hematopoietic recovery 3 month , survival clonal evolution paroxysmal nocturnal hemoglobinuria ( PNH ) , myelodysplasia acute leukemia secondary endpoint .</brief_summary>
	<brief_title>Rabbit Antithymocyte Globulin Versus Campath-1H Treating Severe Aplastic Anemia</brief_title>
	<detailed_description>Severe aplastic anemia , characterize pancytopenia hypocellular bone marrow , effectively treat immunosuppressive therapy , usually combination antithymocyte globulin ( ATG ) cyclosporine ( CsA ) . Survival rate follow regimen equivalent achieve allogeneic stem cell transplantation . However , approximately 1/3 patient show blood count improvement ATG/CsA . General experience small pilot study suggest patient may benefit immunosuppression . Furthermore , analysis clinical data suggest patient poor blood count response single course ATG , even transfusion-independence achieve , markedly bad prognosis patient robust hematologic improvement . The management case uncertain . This study enroll patient either refractory h-ATG ( continue severe pancytopenia ) modest improvement blood count ( weak hematologic responder ) receive immunosuppressive therapy , deliver either rabbit ATG ( Thymoglobulin , r-ATG ) humanize monoclonal antibody T-cells , alemtuzumab ( Campath-1H ) . Primary endpoint response rate 6 month define longer meet criterion severe aplastic anemia . Relapse , robustness hematopoietic recovery 6 month , survival clonal evolution paroxysmal nocturnal hemoglobinuria ( PNH ) , myelodysplasia acute leukemia secondary endpoint .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>INCLUSION CRITERIA : Severe aplastic anemia confirm NIH : Bone marrow cellularity le 30 % ( exclude lymphocyte ) At least two follow : Absolute neutrophil count le 500/microL ; Platelet count le 20,000/ microL ; Reticulocyte count le 60,000/ microL . Severe aplastic anemia refractory prior course ( ) hATG/CsA define 3 month treatment less equal 4 year receive hATG . OR Suboptimal response initial immunosuppression hATG/CsA define platelet reticulocyte count le 50,000 /microL 3 month . Age great equal 2 year age EXCLUSION CRITERIA : Diagnosis Fanconi anemia . Evidence clonal disorder cytogenetics . Patients super severe neutropenia ( ANC le 200/microL ) exclude initially result cytogenetics available pending . If evidence clonal disorder later identify , subject go study . Prior treatment course rabbit ATG high dose cyclophosphamide ( 200 mg/kg equivalent ) . Infection adequately respond appropriate therapy . Underlying immunodeficiency state include seropositivity HIV . Failure discontinue herbal supplement Echinacea purpurea Usnea barbata ( Old Man 's Beard ) within two week enrollment . Previous hypersensitivity Campath1H component . Moribund status concurrent hepatic , renal , cardiac , neurologic , pulmonary , infectious , metabolic disease severity would preclude patient ability tolerate protocol therapy death within 710 day likely . Potential subject cancer active chemotherapeutic treatment take drug hematological effect eligible . Serum creatinine great 2.5 mg/dL . Current pregnancy lactation unwillingness take contraceptive . Inability understand investigational nature study give inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Alemtuzumab ( Campath-1H )</keyword>
	<keyword>Rabbit ATG</keyword>
	<keyword>Severe Aplastic Anemia</keyword>
	<keyword>Cyclosporine</keyword>
	<keyword>Thrombocytopenia</keyword>
	<keyword>Leukopenia</keyword>
	<keyword>Neutropenia</keyword>
	<keyword>Autoimmunity</keyword>
	<keyword>Relapse</keyword>
	<keyword>Anemia</keyword>
</DOC>